-
SELLAS Life Sciences Stock Soars 166% After Phase 3 REGAL Leukemia Vaccine Trial Meets Its Survival Goal, With a Further 5% Gain Reported on 18 November
- November 19, 2026
- Posted by: Ankit Jaiswal
- Category: News
No Comments
SELLAS Life Sciences stock jumped about 166 percent after its Phase 3 REGAL leukemia vaccine trial met its survival goal: the data, the filing plan, short interest and risks.